Subject(s)
Animals , Female , Humans , Infant, Newborn , Pregnancy , Pandemics , Zika Virus/physiology , Zika Virus Infection/epidemiology , Argentina/epidemiology , Pregnancy Complications, Infectious/epidemiology , Pregnancy Complications, Infectious/virology , Congenital Abnormalities/etiology , Congenital Abnormalities/virology , Global Health , Aedes/virology , Neural Stem Cells/virology , Zika Virus/isolation & purification , Zika Virus Infection/transmission , Zika Virus Infection/virology , Genotype , Insect Vectors/virology , Macaca mulatta/virologyABSTRACT
Among the flaviviruses, dengue, with its four serotypes, has spread throughout the tropics. The most advanced vaccines developed so far include live attenuated viruses, which have been tested in humans but none has been licensed. Preclinical testing of dengue vaccine candidates is performed initially in mice and in nonhuman primates. In the latter the main criteria used to assay protection are neutralizing antibodies elicited by the vaccine candidate and the magnitude and duration of peripheral viremia upon challenge of previously immunized animals. Towards the identification of wild-type viruses that could be used in challenge experiments a total of 31 rhesus monkeys were inoculated subcutaneously of wild dengue types 1, 2, and 3 viruses. The viremia caused by the different viruses was variable but it was possible to identify dengue viruses useful as challenge strains.